Natera (NTRA) Raised to “Hold” at BidaskClub

BidaskClub upgraded shares of Natera (NASDAQ:NTRA) from a sell rating to a hold rating in a research report report published on Monday morning.

NTRA has been the subject of several other reports. ValuEngine downgraded Natera from a strong-buy rating to a buy rating in a report on Wednesday, January 9th. Zacks Investment Research downgraded Natera from a hold rating to a sell rating in a report on Thursday, January 10th. Finally, Canaccord Genuity restated a buy rating and issued a $25.00 price objective on shares of Natera in a report on Monday, March 11th. Three investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. The stock currently has a consensus rating of Buy and an average target price of $27.75.

NASDAQ:NTRA opened at $20.30 on Monday. Natera has a twelve month low of $8.60 and a twelve month high of $29.62. The firm has a market cap of $1.21 billion, a PE ratio of -9.44 and a beta of 1.84. The company has a quick ratio of 2.32, a current ratio of 2.11 and a debt-to-equity ratio of 2.28.

Natera (NASDAQ:NTRA) last released its earnings results on Tuesday, March 12th. The medical research company reported ($0.51) earnings per share for the quarter, hitting the consensus estimate of ($0.51). Natera had a negative return on equity of 790.13% and a negative net margin of 49.72%. The business had revenue of $67.00 million during the quarter, compared to the consensus estimate of $62.87 million. On average, sell-side analysts anticipate that Natera will post -2.24 earnings per share for the current year.

In related news, insider Jonathan Sheena sold 23,356 shares of Natera stock in a transaction dated Wednesday, March 13th. The stock was sold at an average price of $20.51, for a total value of $479,031.56. Following the completion of the sale, the insider now directly owns 294,758 shares in the company, valued at $6,045,486.58. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Michael Burkes Brophy sold 3,192 shares of Natera stock in a transaction dated Monday, March 11th. The shares were sold at an average price of $16.00, for a total value of $51,072.00. Following the completion of the sale, the chief financial officer now owns 13,422 shares of the company’s stock, valued at $214,752. The disclosure for this sale can be found here. Insiders sold 40,194 shares of company stock valued at $742,949 over the last 90 days. 13.18% of the stock is currently owned by corporate insiders.

Hedge funds have recently added to or reduced their stakes in the stock. FMR LLC grew its stake in Natera by 57.0% in the fourth quarter. FMR LLC now owns 3,908,921 shares of the medical research company’s stock valued at $54,568,000 after purchasing an additional 1,419,390 shares during the last quarter. Jennison Associates LLC grew its stake in Natera by 1.8% in the fourth quarter. Jennison Associates LLC now owns 3,706,873 shares of the medical research company’s stock valued at $51,748,000 after purchasing an additional 65,025 shares during the last quarter. Vanguard Group Inc grew its stake in Natera by 28.9% in the third quarter. Vanguard Group Inc now owns 3,612,860 shares of the medical research company’s stock valued at $86,493,000 after purchasing an additional 808,976 shares during the last quarter. Vanguard Group Inc. grew its stake in Natera by 28.9% in the third quarter. Vanguard Group Inc. now owns 3,612,860 shares of the medical research company’s stock valued at $86,493,000 after purchasing an additional 808,976 shares during the last quarter. Finally, BlackRock Inc. grew its stake in Natera by 33.5% in the third quarter. BlackRock Inc. now owns 2,785,208 shares of the medical research company’s stock valued at $66,679,000 after purchasing an additional 698,379 shares during the last quarter. Hedge funds and other institutional investors own 89.44% of the company’s stock.

About Natera

Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.

Read More: How to Invest in the Dividend Aristocrat Index

Analyst Recommendations for Natera (NASDAQ:NTRA)

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.